FDA – Page 297 – Pharma.Tips

Ivrt Failure during EU/UK market supply: process parameter review and validation impact

Investigating IVRT Failures Impacting EU/UK Market Supply: A Process Review In the pharmaceutical industry, ensuring the efficacy and safety of products is a paramount concern. Among various quality assurance measures,…

Fill Weight Variability during homogenization: GMP investigation and CAPA strategy

Investigating Fill Weight Variability during Homogenization: A GMP Approach In pharmaceutical manufacturing, maintaining consistency in product fill weights is crucial to meet the stringent requirements of regulatory agencies. Fill weight…

Ivpt Failure during EU/UK market supply: process parameter review and validation impact

Investigation of Ivpt Failure in EU/UK Market Supply: Reviewing Process Parameters and Validation Impact In pharmaceutical manufacturing, in vitro permeation testing (IVPT) is crucial for ensuring the efficacy and safety…

Pet Failure during sterile filtration: CAPA and effectiveness check plan

Addressing Pet Failures during Sterile Filtration: An Investigation Approach Pet failures during sterile filtration present significant challenges in pharmaceutical manufacturing, particularly in the production of ophthalmic dosage forms. The inability…

Phase Separation during bulk hold: mixing and sampling controls for QA review

Investigating Phase Separation During Bulk Hold: Essential Controls for Quality Assurance In the pharmaceutical manufacturing landscape, maintaining product integrity during storage is paramount. Phase separation during bulk hold can lead…

Coating Weight Variability after backing material change: root cause mapping across materials and process

Investigating Coating Weight Variability Following Backing Material Changes Coating weight variability is a common concern within pharmaceutical manufacturing, particularly following changes in backing materials. Fluctuations in coating weight can impact…

Color Change at accelerated stability: mixing and sampling controls for QA review

Identifying and Investigating Color Change During Accelerated Stability for Quality Assurance Color change during accelerated stability testing can present significant challenges in pharmaceutical manufacturing, particularly for topical and dermatological dosage…

Ivrt Failure during scale-up: root cause mapping across materials and process

Root Cause Mapping for IVRT Failures during Scale-Up in Pharmaceutical Manufacturing In the highly regulated world of pharmaceutical manufacturing, any deviations or out-of-specification (OOS) results can lead to significant disruptions,…

Osmolality Oos at stability pull: CAPA and effectiveness check plan

Osmolality is a critical parameter in ensuring the quality of pharmaceutical formulations, particularly in ophthalmic dosage forms. When an out-of-specification (OOS) result occurs during a stability pull, it can lead…

Dose Delivery Variability during lamination: inspection-ready documentation pack

Addressing Variability in Dose Delivery during Lamination: A Comprehensive Investigation In pharmaceutical manufacturing, particularly in the development of transdermal drug delivery systems, maintaining consistent dose delivery is crucial. When variability…

Texture Variability at accelerated stability: packaging compatibility and stability justification

Understanding Texture Variability During Accelerated Stability Testing in Pharmaceutical Manufacturing Texture variability observed during accelerated stability testing can raise significant concerns regarding product quality and consistency, particularly for topical and…

Ivpt Failure in transdermal patch manufacturing: packaging integrity and shelf-life justification

Investigation of IVPT Failures during Transdermal Patch Manufacturing: Packaging Integrity and Shelf-Life Considerations In the increasingly complex landscape of pharmaceutical manufacturing, ensuring the integrity and efficacy of transdermal patches poses…